Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 2, 2013, Pages 106-111

  Casulo, Carla ^a   Maragulia, Jocelyn ^a   Zelenetz, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gamma globulin; Hypogammaglobulinemia; Infections; Lymphoma; Rituximab

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHILD; CHRONIC LYMPHATIC LEUKEMIA; DRUG USE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOGLOBULIN M DEFICIENCY; INCIDENCE; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CHILD; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; INFECTION; LYMPHOMA, B-CELL; MIDDLE AGED; YOUNG ADULT;

EID: 84877359983     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.11.011     Document Type: Article

References (37)

1. D.G. Maloney, A.J. Grillo-López, D.J. Bodkin IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J Clin Oncol 15 1997 3266 3274 (Pubitemid 27419340)
2. D.G. Maloney, A.J. Grillo-López, C.A. White IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90 1997 2188 2195 (Pubitemid 27392702)
3. P. McLaughlin, A.J. Grillo-López, B.K. Link Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 1998 2825 2833 (Pubitemid 28363048)
4. B. Coiffier, E. Lepage, J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235 242 (Pubitemid 34438862)
5. P. Feugier, A. Van Hoof, C. Sebban Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 2005 4117 4126 (Pubitemid 46211317)
6. M. Pfreundschuh, L. Trümper, A. Osterborg Chop-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 2006 379 391
7. M. Hallek, K. Fischer, G. Fingerle-Rowson Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 376 2010 1164 1174
8. T. Robak, A. Dmoszynska, P. Solal-Céligny Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia J Clin Oncol 28 2010 1756 1765
9. P.J. Mease, D.A. Revicki, J. Szechinski Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial J Rheumatol 35 2008 20 30
10. J. Mangel, H.A. Leitch, J.M. Connors Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis Ann Oncol 15 2004 283 290 (Pubitemid 38262629)
11. W. Brugger, J. Hirsch, F. Grünebach Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study Ann Oncol 15 2004 1691 1698 (Pubitemid 39562612)
12. S.M. Horwitz, R.S. Negrin, K.G. Blume Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma Blood 103 2004 777 783 (Pubitemid 38129532)
13. F. Neumann, S. Harmsen, S. Martin Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma Ann Hematol 85 2006 530 534 (Pubitemid 44303921)
14. T.M. Habermann, E.A. Weller, V.A. Morrison Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 2006 3121 3127 (Pubitemid 46638950)
15. C. Haioun, N. Mounier, J.F. Emile Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma Ann Oncol 20 2009 1985 1992
16. L.K. Hicks, A. Woods, R. Buckstein Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma Bone Marrow Transplant 43 2009 701 708
17. V.P. Kenkre, W.L. Long, J.C. Eickhoff Maintenance rituximab following induction chemoimmunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network Leuk Lymphoma 52 2011 1675 1680
18. K. Chaiwatanatorn, N. Lee, A. Grigg Delayed-onset neutropenia associated with rituximab therapy Br J Haematol 121 2003 913 918 (Pubitemid 36760311)
19. Y. Tsutsumi, H. Kanamori, A. Mori Reactivation of hepatitis B virus with rituximab Expert Opin Drug Saf 4 2005 599 608 (Pubitemid 40723731)
20. G.B. Fogarty, M. Bayne, P. Bedford Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab Clin Oncol (R Coll Radiol) 18 2006 155 156 (Pubitemid 43169149)
21. K.R. Carson, D. Focosi, E.O. Major Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project Lancet Oncol 10 2009 816 824
22. N. Cooper, D.M. Arnold The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases Br J Haematol 149 2010 3 13
23. M. Nishio, K. Fujimoto, S. Yamamoto Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma Eur J Haematol 77 2006 226 232 (Pubitemid 44181385)
24. F. Cabanillas, I. Liboy, O. Pavia High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication Ann Oncol 17 2006 1424 1427 (Pubitemid 44400381)
25. C. Arber, A. Buser, D. Heim Septic polyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment Bone Marrow Transplant 40 2007 597 598 (Pubitemid 47382132)
26. N. Cooper, E.G. Davies, A.J. Thrasher Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin Br J Haematol 146 2009 120 122
27. L. Diwakar, S. Gorrie, A. Richter Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 63 2010 275 277
28. S. Sclove A review of statistical model selection criteria: application to prediction in regression, histograms, and finite mixture models 2011:1-40 http://papers.ssrn.com/sol3/papers.cfm?abstract-id=1910768# Accessed: May 15, 2012
29. J. Orange Position statement on the appropriate use of intravenously administered immunoglobulin (IVIG) AAAAI position paper: use of IVIG American Acad of Allergy, Asthma And Immunol 2005 http://www.aaaai.org/Aaaai/media/ MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/IGIV-2005.pdf Accessed: January 2012
30. J. de Gracia, M. Vendrell, A. Alvarez Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency Int Immunopharmacol 4 2004 745 753 (Pubitemid 38595531)
31. C.M. Roifman, H. Levison, E.W. Gelfand High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease Lancet I 1987 1075 1077 (Pubitemid 17061340)
32. P. Quartier, M. Debré, J. De Blic Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients J Pediatr 134 1999 589 596 (Pubitemid 30180599)
33. A.D. Zelenetz, J.S. Abramson, R.H. Advani Non-Hodgkin's lymphomas J Natl Compr Cancer Netw JNCCN 9 2011 484 560
34. S. Aksoy, O. Dizdar, M. Hayran Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis Leuk Lymphoma 50 2009 357 365
35. R.H. Buckley, R.I. Schiff The use of intravenous immune globulin in immunodeficiency diseases N Engl J Med 325 1991 110 117
36. V.A. Morrison, K.R. Rai, B.L. Peterson Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011 J Clin Oncol 19 2001 3611 3621 (Pubitemid 32791321)
37. J.C. Byrd, L.H. McGrail, D.R. Hospenthal Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study Br J Haematol 105 1999 445 447 (Pubitemid 29232169)